CORT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Corcept Therapeutics Inc. (CORT) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock has faced significant negative catalysts, including regulatory setbacks and declining financial performance. While analysts maintain a Buy rating with high price targets, the recent FDA issues and ongoing investigations create uncertainty. It is better to hold off on investing until more clarity emerges around the company's drug pipeline and financial recovery.
The technical indicators show a bearish trend with the stock trading below key moving averages (SMA_200 > SMA_20 > SMA_5). The RSI is neutral at 32.815, and the MACD is above zero but contracting, indicating weakening momentum. The stock is near its support level of 37.669, with resistance at 39.755 and 41.841.
based on potential growth in Korlym and relacorilant for ovarian cancer. The company reported positive Phase III trial data for relacorilant in platinum-resistant ovarian cancer, with an FDA action date set for July 11, 2026.
The FDA issued a Complete Response Letter for relacorilant in Cushing's syndrome, delaying its market entry and raising concerns about the drug's approval. Multiple law firms are investigating securities fraud claims against the company. Recent news has negatively impacted investor confidence, with the stock dropping significantly. Additionally, financial performance in Q3 2025 showed a sharp decline in net income (-58.34%) and EPS (-61.90%).
In Q3 2025, revenue increased by 13.75% YoY to $207.6M, but net income dropped by 58.34% YoY to $19.7M. EPS also declined by 61.90% YoY to $0.16, and gross margin slightly decreased to 97.79%. The financial performance reflects growth in revenue but significant pressure on profitability.
Analysts maintain a generally positive outlook with Buy ratings and high price targets ($99-$105). However, Wolfe Research downgraded the stock to Underperform with a $30 price target, citing regulatory challenges and uncertainty around relacorilant's approval for Cushing's syndrome.
